Rana R. McKay, MD

Articles

First-Line Therapy in Advanced Clear Cell RCC: Novel Triplet Regimens

October 20th 2022

Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.

First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet Regimens

October 20th 2022

An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.

Advanced Clear Cell RCC: Quality of Life Data in First-Line Clinical Trials

October 13th 2022

Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.

Treating Patients with Clear Cell RCC with Brain Metastases or Sarcomatoid Disease

October 13th 2022

Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.

Advanced Clear Cell RCC: Role of Site of Metastases in Selecting First-Line Therapy

October 6th 2022

Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.

Selecting the Appropriate First-Line Therapy in Advanced Clear Cell RCC

October 6th 2022

Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.

What is the Role of Nephrectomy in Advanced Clear Cell RCC?

September 29th 2022

Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.

Overview on Clear Cell Renal Cell Carcinoma: Prevalence and Prognosis

September 29th 2022

Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.

Frontline Therapeutic Planning for Metastatic Renal Cell Carcinoma

November 18th 2020

In this review, authors highlight multidisciplinary treatment for patients with advanced disease, and integrating systemic therapy options with surgery and radiation therapy.

Dr. McKay on the Role of Age and Gender in Advanced RCC Outcomes

August 13th 2020

Rana R. McKay, MD, discusses the role of age and gender in advanced renal cell carcinoma outcomes.

Dr. McKay on the Design of the PDIGREE Trial in Advanced RCC

June 25th 2020

Rana R. McKay, MD, discusses the design of the phase 3 PDIGREE study in advanced renal cell carcinoma.

Dr. McKay on Adapting Treatment for Patients With Cancer in COVID-19 Era

June 3rd 2020

Rana R. McKay, MD, discusses adapting treatment for patients with cancer during the coronavirus disease 2019 pandemic.

Dr. McKay on Evaluating Radium-223 in HRD-Mutant mCRPC

April 25th 2020

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses planned research in which investigators will evaluate the use of radium-223 dichloride (Xofigo) in patients with homologous recombination deficiency (HRD)-mutant metastatic castration-resistant prostate cancer (mCRPC).

Dr. McKay on the Utility of Radium-223 in the Treatment of mCRPC

April 9th 2020

Rana R. McKay, MD, discusses the utility of radium-223 in metastatic castration-resistant prostate cancer.

Dr. McKay on Rationale for Real-World Analysis of Radium-223 in mCRPC

March 27th 2020

Rana R. McKay, MD, discusses the rationale for conducting a real-world analysis of radium-223 dichloride in metastatic castration-resistant prostate cancer.

Dr. McKay on the Real-World Utilization of Radium-223 in mCRPC

March 13th 2020

Rana R. McKay, MD, discusses results from an analysis examining the real-world utilization of radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Dr. McKay on a Real-World Analysis of Radium-223 in mCRPC

February 27th 2020

Rana R. McKay, MD, discusses the results of a real-world analysis of radium-223 in patients with metastatic castration-resistant prostate cancer.

Dr. McKay on FDA Approval of Nivolumab/Ipilimumab in Frontline RCC

April 16th 2018

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses the FDA approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) in patients with renal cell carcinoma (RCC).

Dr. McKay on Unmet Needs for RCC

February 23rd 2018

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses unmet needs for patients with renal cell carcinoma (RCC).

Dr. McKay Discusses Combinations in Renal Cell Carcinoma

January 24th 2018

Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses combinations in renal cell carcinoma.